Evidence map›Paper›PMID 41313745›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Antiemesis Corticosteroids Potentiate Checkpoint Blockade Efficacy by Normalizing the Immune Microenvironment in Metastatic Murine Breast Cancer.

John D Martin, Koji Nagaoka, Myrofora Panagi, Akihiro Hosoi, Fotios Mpkeris, Pengwen Chen, Thahomina T Khan, Margaret R Martin, Changbo Sun, Chrysovalantis Voutouri and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

John D MartinDepartment of Bioengineering, Graduate School of Engineering, The University of Tokyo, Bunkyo, Tokyo, 113-8656, Japan.ORCID https://orcid.org/0000-0002-9828-8203
Koji NagaokaDepartment of Immunotherapeutics, The University of Tokyo Hospital, Bunkyo, Tokyo, 113-8656, Japan.ORCID https://orcid.org/0000-0001-8202-031X
Myrofora PanagiCancer Biophysics Laboratory, Department of Mechanical and Manufacturing Engineering, University of Cyprus, Nicosia, 1678, Cyprus.ORCID https://orcid.org/0000-0002-6256-3250
Akihiro HosoiDepartment of Immunotherapeutics, The University of Tokyo Hospital, Bunkyo, Tokyo, 113-8656, Japan.
Fotios MpkerisCancer Biophysics Laboratory, Department of Mechanical and Manufacturing Engineering, University of Cyprus, Nicosia, 1678, Cyprus.ORCID https://orcid.org/0000-0002-7125-4062
Pengwen ChenDepartment of Bioengineering, Graduate School of Engineering, The University of Tokyo, Bunkyo, Tokyo, 113-8656, Japan.ORCID https://orcid.org/0000-0002-5663-2192
Thahomina T KhanDepartment of Bioengineering, Graduate School of Engineering, The University of Tokyo, Bunkyo, Tokyo, 113-8656, Japan.ORCID https://orcid.org/0000-0001-6047-6754
Margaret R MartinDepartment of Bioengineering, Graduate School of Engineering, The University of Tokyo, Bunkyo, Tokyo, 113-8656, Japan.ORCID https://orcid.org/0000-0001-6631-9434
Changbo SunDepartment of Immunotherapeutics, The University of Tokyo Hospital, Bunkyo, Tokyo, 113-8656, Japan.ORCID https://orcid.org/0000-0002-2606-2694
Chrysovalantis VoutouriCancer Biophysics Laboratory, Department of Mechanical and Manufacturing Engineering, University of Cyprus, Nicosia, 1678, Cyprus.ORCID https://orcid.org/0000-0003-3172-9489
Maria LoucaCancer Biophysics Laboratory, Department of Mechanical and Manufacturing Engineering, University of Cyprus, Nicosia, 1678, Cyprus.ORCID https://orcid.org/0000-0001-8595-3828
Panagiotis PapageorgisCancer Biophysics Laboratory, Department of Mechanical and Manufacturing Engineering, University of Cyprus, Nicosia, 1678, Cyprus.ORCID https://orcid.org/0000-0002-7595-5616
Akira SumiyoshiNational Institute of Radiological Sciences, Japan Agency for Quantum and Radiological Science and Technology, Anagawa 4-9-1, Inage, Chiba, 263-8555, Japan.ORCID https://orcid.org/0000-0001-9522-8064
Nobuhiro NittaNational Institute of Radiological Sciences, Japan Agency for Quantum and Radiological Science and Technology, Anagawa 4-9-1, Inage, Chiba, 263-8555, Japan.
Kazuyoshi TakedaDivision of Cell Biology, Biomedical Research Center, Juntendo University, Bunkyo, Tokyo, 113-8421, Japan.
Ichio AokiNational Institute of Radiological Sciences, Japan Agency for Quantum and Radiological Science and Technology, Anagawa 4-9-1, Inage, Chiba, 263-8555, Japan.ORCID https://orcid.org/0000-0002-4429-5053
Kazunori KataokaInnovation Center of NanoMedicine, Kawasaki Institute of Industrial Promotion, Kawasaki, Kanagawa, 210-0821, Japan.ORCID https://orcid.org/0000-0002-8591-413X
Triantafyllos StylianopoulosCancer Biophysics Laboratory, Department of Mechanical and Manufacturing Engineering, University of Cyprus, Nicosia, 1678, Cyprus.ORCID https://orcid.org/0000-0002-3093-1696
Kazuhiro KakimiDepartment of Immunotherapeutics, The University of Tokyo Hospital, Bunkyo, Tokyo, 113-8656, Japan.ORCID https://orcid.org/0000-0003-2631-3040
Horacio CabralDepartment of Bioengineering, Graduate School of Engineering, The University of Tokyo, Bunkyo, Tokyo, 113-8656, Japan.ORCID https://orcid.org/0000-0002-4030-2631

Funding

European Regional Development FundGrants-in-Aid Challenging Research 18H05378Grants-in-Aid for Exploratory Research 22K19541Grants-in-Aid for Scientific Research A 23H00546HORIZON EUROPE European Research Council ERC-2013-StG-336839HORIZON EUROPE European Research Council ERC-2018-PoC-838414HORIZON EUROPE European Research Council ERC-2019-CoG-863955Japan Agency for Medical Research and Development JP17cm0106202Japan Society for the Promotion of Science P16731Ministry of Education, Culture, Sports, Science and TechnologyPromotion of Joint International Research 21KK0197Research Promotion Foundation INFRASTRUCTURE/1216/0052Research Promotion Foundation POST-DOC/0718/0084
6 · The paper itself

Abstract

Glucocorticoid steroids are widely prescribed in oncology for managing treatment-related side effects, though their use is discouraged in patients undergoing immune checkpoint blockade (ICB). Given the crucial role of steroids in supportive care, it is imperative to develop integrated strategies that do not compromise ICB therapy effectiveness. Here, protocols of dexamethasone resembling clinical antiemesis regimens are tested in murine models of ICB-resistant breast cancer. Unexpectedly, dexamethasone enhanced the efficacy of ICB in models of primary cancer and spontaneous metastasis. Dexamethasone increased the volume of blood vessels within tumors, thereby facilitating lymphocyte infiltration and intratumor distribution. Additionally, dexamethasone depleted immunosuppressive cells and potentiated the capacity of ICB to enrich tumors of antigen-recognizing cytotoxic lymphocytes. Importantly, it is found that dexamethasone does not abolish the functions of antigen-naïve lymphocytes and has no effect on the activity of antigen-experienced lymphocytes. These findings align with recent clinical guidelines and meta-analyses, suggesting that dexamethasone deserves further exploration in ICB protocols to potentially benefit efficacy. Our study supports the notion that the current practice of avoiding short-term glucocorticoid steroids in patients receiving ICB should be reconsidered toward enabling the use of steroids in clinical trials of new drug combinations.

Indexed as

Adrenal Cortex HormonesBreast NeoplasmsDexamethasoneImmune Checkpoint InhibitorsTumor MicroenvironmentAnimalsCell Line, TumorDisease Models, AnimalFemaleGlucocorticoidsMiceAdrenal Cortex HormonesDexamethasoneGlucocorticoidsImmune Checkpoint Inhibitors3D magnetic resonance (MR) angiographyanti‐PD‐1 and anti‐CTLA‐4 antibodiesbreast cancerdexamethasonetumor normalizationtumor perfusion

Identifiers

PMID41313745
PMCPMC12970202

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.